http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
9 Meters Biopharma, Inc. highlighted at upcoming Truist Securities' CEO Strategic Vision Conference Call Series
-
9 Meters Biopharma, Inc. Announces Research & Development Day on Short Bowel Syndrome
-
9 Meters Biopharma (NMTR) Announces Agreement with European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications
-
9 Meters Biopharma Announces Agreement with the European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications
-
9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock
-
UPDATE: 9 Meters Biopharma (NMTR) Prices 46.154M Share Common Offering at $0.65/Sh
-
9 Meters Biopharma, Inc. Prices Public Offering of Common Stock
-
9 Meters Biopharma, Inc. Announces Proposed Public Offering of Common Stock
-
9 Meters Biopharma (NMTR) Receives Orphan Drug Designation for NM-003, Proprietary Long-Acting GLP-2, for Prevention of aGvHD
-
9 Meters Biopharma, Inc. Receives Orphan Drug Designation for NM-003, a Proprietary Long-Acting GLP-2, for Prevention of Acute Graft Versus Host Disease (aGvHD)
-
9 Meters Biopharma (NMTR) Announces Positive Topline Data for NM-002, a Proprietary Long-Acting GLP-1, in Phase 1b/2a Trial for Short Bowel Syndrome
-
9 Meters Biopharma, Inc. Announces Positive Topline Data for NM-002, a Proprietary Long-Acting GLP-1, in Phase 1b/2a Trial for Short Bowel Syndrome
-
UPDATE: 9 Meters Biopharma (NMTR) Reports Positive Preclinical Data for NM-102
-
9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model
-
9 Meters Biopharma, Inc. to Participate in the Following November Virtual Investor Conferences
-
9 Meters Biopharma, Inc. to Participate in September Investor Conferences
-
9 Meters Biopharma, Inc. Announces Formation of Scientific Advisory Board
-
9 Meters Biopharma, Inc. Highlighted at Upcoming Truist Securities' Catalyst Conference Call Series: "Prepping Ahead of Data"
-
9 Meters Biopharma, Inc. Provides Business Update and Announces Second Quarter 2020 Results
-
9 Meters Biopharma, Inc. to Participate in August Investor Conferences
-
9 Meters Biopharma, Inc. Announces Issuance of Patent for Use of Larazotide in Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS)
-
9 Meters Biopharma, Inc. Doses the First Patients in Phase 1b/2a Clinical Trial in Short Bowel Syndrome

